(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a prostate cancer poster session. Dr. Matthew Cooperberg presented a study using a validated pathology-based multimodal artificial intelligence (MMAI) biomarker to predict long-term outcomes following radical prostatectomy (RP).
RP improves metastasis-free and overall survival in higher risk localized prostate cancer patients,1 but outcomes vary dramatically with baseline risk characteristics. Predictive biomarkers for improved risk stratification and treatment-decision making after RP require tissue destruction and are subject to intratumor variability. MMAI models utilizing image analysis of standard clinical pathology biopsy slides have previously been validated as…